期刊
MULTIPLE SCLEROSIS JOURNAL
卷 14, 期 5, 页码 622-630出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458507087136
关键词
autoimmune diseases; cytokines; immunotherapy; interferon-beta treatment; interleukin-10; interleukin-23; multiple sclerosis
Background Interferon ( IFN)-beta therapy in multiple sclerosis ( MS) has been suggested to promote a deviation from T lymphocyte production of pathogenic Th1 cytokines to less detrimental Th2 cytokines, but this is still controversial. We studied patterns of in vivo blood mononuclear cell ( MNC) and whole blood cytokine and transcription factor mRNA expression before and during IFN-beta therapy in MS. Methods Twenty patients with relapsing-remitting MS were sampled before and after 3 months of treatment with IFN-beta along with 15 healthy volunteers. An additional 39 patients and 50 healthy volunteers served to confirm initial findings. mRNA was analyzed by real-time reverse transcriptase polymerase chain reaction (PCR). Results We found elevated expression of interleukin ( IL)-23 and IL-10 in untreated MS patients. IFN-beta therapy increased IL-10 and decreased IL-23 expression independently of any Th1 or Th2 cytokines. The largest changes in cytokine mRNA levels occurred early (similar to 9-12 h) after an IFN-beta injection. Conclusion We found no evidence of a Th1- or Th2- mRNA- promoting effect of IFN-beta therapy. The therapeutic effect of IFN-beta is more likely attributable to the induction of the regulatory cytokine IL-10. The elevated IL-23 mRNA levels in MS patients are noteworthy in view of the newly discovered IL-23- driven Th17 T-cell subset, which is crucial in animal models of MS. Since IFN-beta therapy resulted in decreased IL-23 mRNA levels, the Th17 axis could be another target of IFN-beta therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据